FDA warning

FDA Issues Warning for EluxadolineAnti-IBS drug Viberzi (eluxadoline) increases risk of severe pancreatitis.
Pfizer Receives FDA Warning
Pfizer Receives FDA WarningA Pfizer plant in Kansas is putting patients at risk, according to the FDA
Major allergic reactions linked to common antisepticsFDA is warning about rare but serious allergic reactions have from the widely-used skin antiseptic products containing chlorhexidine gluconate.
FDA issues warnings over anesthesia, diabetes drugsFDA issued two important drug warnings this week: one linking certain diabetes medications to bladder cancer and another about the use of general anesthetic and sedation drugs during pregnancy.
New kidney warning on popular diabetes drugsSoon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).
Teva halts migraine patch sales over burnsTeva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.
FDA warns about Cipro, other antibacterialsFDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.
FDA increases warning on diabetes medicationThe FDA has strengthened its warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density.
MS drug linked to rare brain infectionFDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).
Prescribing, dispensing errors seen with Brintellix, BrilintaFDA issued a drug safety warning that there have been 50 reports of medication errors because of confusion between the antidepressant Brintellix (vortioxetine) and the antiplatelet agent Brilinta (ticagrelor).